VECT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 Jul 2023 @ 15:59):

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions...

Stats
Today's Volume	127 653
Average Volume	1.10M
Market Cap	1.06B
EPS	$0 ( 2023-07-19 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.03
ATR14	$0.430 (2.55%)

Volume Correlation

Long: 0.33 (neutral)

Short: -0.50 (neutral)

Signal:(67.1) Neutral

VectivBio Holding AG Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

VectivBio Holding AG Correlation - Currency/Commodity

0.77
( moderate )

0.76
( moderate )

-0.45
( neutral )

0.60
( weak )

-0.28
( neutral )

-0.07
( neutral )

VectivBio Holding AG Financials

Annual	2022
Revenue:	$27.34M
Gross Profit:	$27.34M (100.00 %)
EPS:	$-2.12

Q4	2022
Revenue:	$676 000
Gross Profit:	$676 000 (100.00 %)
EPS:	$-0.650

Financial Reports:

No articles found.

VectivBio Holding AG

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.